Merck Kgaa Unsp ADR (MKGAY) 36.0300 $MKGAY
Tert-butanol Market - Tert-Butanol Manufacturers Going Green as Governments Crack Down on VOC Emitting Solvents; Global Industry Analysis and forecast 2016 - 2024
PR Newswire - Wed Jul 20, 9:00AM CDT
The top five companies competing in the global tert-butanol market, namely LyondellBasell Industries Holdings B.V., Lotte Chemical Titan Corporation, Evonik Industries AG, TonenGeneral Sekiyu K.K., and Merck KGaA, accounted for a share of 43.2% in 2015. This reflects the moderately consolidated nature of the market. Analyzing the medium-level of competition among these and other players, Transparency Market Research has zeroed in on extensive research and development as the key strategy adopted by most. R&D activities focused on increasing the effectiveness of tert-butanol applications have surged in recent times.
MRK: 58.60 (+0.24)
High-throughput End-user Requirements to Boost Instruments Segment in Global Sample Preparation Market, says TMR
PR Newswire Europe - Wed Jul 20, 6:31AM CDT
ALBANY, New York, July 20, 2016 /PRNewswire/ --
PKI: 55.81 (+0.37)
MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts
CNW Group - Tue Jul 19, 7:00AM CDT
- New campus will serve as major life science hub for Merck KGaA, Darmstadt, Germany, with state-of-the-art laboratory for customer collaboration
Merck KGaA, Darmstadt, Germany Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets
CNW Group - Mon Jul 18, 7:00AM CDT
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product, Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).
EMD Serono Commits EUR 1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17
PR Newswire - Wed Jul 06, 10:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling EUR 1.5 million in 2016/17. The announcement was made at the 32nd annual meeting of European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Helsinki, Finland.
Merck KGaA / Merck Serono Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:22PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
MRK: 58.60 (+0.24)
New Data at CMSC Assess Real-World Impact of Rebif® (interferon beta-1a) in People with Relapsing MS
PR Newswire - Thu Jun 02, 8:00AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that it will present real-world data that evaluate relapse rates, outcomes of disease activity and healthcare costs in patients initiating Rebif® (interferon beta-1a) at the 2016 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place June 1-4, 2016, in National Harbor, MD.
NCCN Receives Funding for Policy and Advocacy Fellow
Marketwired - Mon May 23, 10:33AM CDT
Through Funding From EMD Serono, NCCN Is Instituting a Policy and Advocacy Fellowship Designed for Implementation of Policy Programs That Will Enhance Access to and Delivery of Quality Oncology Care in the United States and Globally
EMD Serono Supports Military Community By Providing Access to Fertility Care Through Focused Patient Assistance Programs
PR Newswire - Thu May 19, 8:00AM CDT
In recognition of Military Appreciation Month, EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is working to bridge significant gaps in coverage of fertility treatment for eligible active U.S. military and veterans who have been injured in service and are uninsured through its Compassionate Corps and Compassionate Care programs.
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
BusinessWire - Wed May 18, 4:30PM CDT
--Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma
PFE: 36.85 (+0.02)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.30 (+0.03), MRK: 58.60 (+0.24)
12th Edition of the EMD Serono Specialty Digest(TM) Now Available
PR Newswire - Mon May 09, 8:44AM CDT
EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced the release of the 12th edition of the EMD Serono Specialty Digest(TM). The Digest, which was featured last week at the Asembia Specialty Pharmacy Summit in Las Vegas, NV, is an industry resource that provides market data on health plans' management of specialty pharmaceuticals in 2015 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
EMD Serono Expands Biopharmaceutical R&D Facility in Billerica, MA to Accelerate Innovation
PR Newswire - Mon May 02, 6:59AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in North America, today announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.20 (-0.08), CBMG: 14.92 (+0.45), OCAT: 8.47 (+0.01), ZBH: 122.68 (-0.94), PFE: 36.85 (+0.02), LLY: 83.40 (+1.31), GSK: 45.12 (+0.96), GLPG: 54.49 (+0.58), AXSM: 7.98 (+0.19), OMER: 11.19 (+0.22), CANF: 2.11 (-0.02), AST: 2.99 (+0.06), AKTX: 8.90 (+0.10)
Saviynt Selected by the Life Science Business of Merck KGaA, Darmstadt, Germany to Secure Its Next-Generation SAP and S/4HANA Platform
Marketwired - Tue Apr 26, 8:03AM CDT
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, has selected Saviynt to provide security administration, governance and compliance management for its SAP NEXT program. As a company that is laser focused on innovation and quality, this announcement follows the results of an extensive evaluation conducted by Merck KGaA, Darmstadt, Germany for a strategic security solutions partner.
Merck KGaA Selects Unisys to Deliver Global End-User IT Services to Support its Growth Strategy
PR Newswire - Tue Apr 26, 7:00AM CDT
Unisys Corporation (NYSE: UIS) today announced that its subsidiary in Germany has won a new five-year contract to provide Merck KGaA with end-user IT services for its 48,000 employees worldwide.
MRK: 58.60 (+0.24), UIS: 10.04 (+2.09)
Tert-butanol Market - Tert-Butanol Manufacturers Going Green as Governments Crack Down on VOC Emitting Solvents; Global Industry Analysis and forecast 2016 - 2024
PR Newswire - Wed Jul 20, 9:00AM CDT
The top five companies competing in the global tert-butanol market, namely LyondellBasell Industries Holdings B.V., Lotte Chemical Titan Corporation, Evonik Industries AG, TonenGeneral Sekiyu K.K., and Merck KGaA, accounted for a share of 43.2% in 2015. This reflects the moderately consolidated nature of the market. Analyzing the medium-level of competition among these and other players, Transparency Market Research has zeroed in on extensive research and development as the key strategy adopted by most. R&D activities focused on increasing the effectiveness of tert-butanol applications have surged in recent times.
MRK: 58.60 (+0.24)
High-throughput End-user Requirements to Boost Instruments Segment in Global Sample Preparation Market, says TMR
PR Newswire Europe - Wed Jul 20, 6:31AM CDT
ALBANY, New York, July 20, 2016 /PRNewswire/ --
PKI: 55.81 (+0.37)
MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts
CNW Group - Tue Jul 19, 7:00AM CDT
- New campus will serve as major life science hub for Merck KGaA, Darmstadt, Germany, with state-of-the-art laboratory for customer collaboration
Merck KGaA, Darmstadt, Germany Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets
CNW Group - Mon Jul 18, 7:00AM CDT
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product, Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).
EMD Serono Commits EUR 1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17
PR Newswire - Wed Jul 06, 10:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling EUR 1.5 million in 2016/17. The announcement was made at the 32nd annual meeting of European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Helsinki, Finland.
Merck KGaA / Merck Serono Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:22PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
MRK: 58.60 (+0.24)
New Data at CMSC Assess Real-World Impact of Rebif® (interferon beta-1a) in People with Relapsing MS
PR Newswire - Thu Jun 02, 8:00AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that it will present real-world data that evaluate relapse rates, outcomes of disease activity and healthcare costs in patients initiating Rebif® (interferon beta-1a) at the 2016 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place June 1-4, 2016, in National Harbor, MD.
NCCN Receives Funding for Policy and Advocacy Fellow
Marketwired - Mon May 23, 10:33AM CDT
Through Funding From EMD Serono, NCCN Is Instituting a Policy and Advocacy Fellowship Designed for Implementation of Policy Programs That Will Enhance Access to and Delivery of Quality Oncology Care in the United States and Globally
EMD Serono Supports Military Community By Providing Access to Fertility Care Through Focused Patient Assistance Programs
PR Newswire - Thu May 19, 8:00AM CDT
In recognition of Military Appreciation Month, EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is working to bridge significant gaps in coverage of fertility treatment for eligible active U.S. military and veterans who have been injured in service and are uninsured through its Compassionate Corps and Compassionate Care programs.
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
BusinessWire - Wed May 18, 4:30PM CDT
--Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma
PFE: 36.85 (+0.02)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.30 (+0.03), MRK: 58.60 (+0.24)
12th Edition of the EMD Serono Specialty Digest(TM) Now Available
PR Newswire - Mon May 09, 8:44AM CDT
EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced the release of the 12th edition of the EMD Serono Specialty Digest(TM). The Digest, which was featured last week at the Asembia Specialty Pharmacy Summit in Las Vegas, NV, is an industry resource that provides market data on health plans' management of specialty pharmaceuticals in 2015 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
EMD Serono Expands Biopharmaceutical R&D Facility in Billerica, MA to Accelerate Innovation
PR Newswire - Mon May 02, 6:59AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in North America, today announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.20 (-0.08), CBMG: 14.92 (+0.45), OCAT: 8.47 (+0.01), ZBH: 122.68 (-0.94), PFE: 36.85 (+0.02), LLY: 83.40 (+1.31), GSK: 45.12 (+0.96), GLPG: 54.49 (+0.58), AXSM: 7.98 (+0.19), OMER: 11.19 (+0.22), CANF: 2.11 (-0.02), AST: 2.99 (+0.06), AKTX: 8.90 (+0.10)
Saviynt Selected by the Life Science Business of Merck KGaA, Darmstadt, Germany to Secure Its Next-Generation SAP and S/4HANA Platform
Marketwired - Tue Apr 26, 8:03AM CDT
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, has selected Saviynt to provide security administration, governance and compliance management for its SAP NEXT program. As a company that is laser focused on innovation and quality, this announcement follows the results of an extensive evaluation conducted by Merck KGaA, Darmstadt, Germany for a strategic security solutions partner.
Merck KGaA Selects Unisys to Deliver Global End-User IT Services to Support its Growth Strategy
PR Newswire - Tue Apr 26, 7:00AM CDT
Unisys Corporation (NYSE: UIS) today announced that its subsidiary in Germany has won a new five-year contract to provide Merck KGaA with end-user IT services for its 48,000 employees worldwide.
MRK: 58.60 (+0.24), UIS: 10.04 (+2.09)
